The panel discussed Dr. Lieu’s case on adjuvant therapy in elderly CRC, emphasizing individualized treatment based on comorbidities, performance status, and ctDNA, with CIRCULATE offering a potential future strategy.

The panel discussed Dr. Sahin’s case on ctDNA-guided care in older CRC patients, highlighting limited oxaliplatin benefit after age 70, persistent ctDNA clearance as a favorable marker, and ongoing biomarker-driven trials.

The panel reviewed Dr. Zakari’s case on rising ctDNA in rectosigmoid cancer, emphasizing clinical trial enrollment, staging laparoscopy, and the need for prospective studies before ctDNA routinely guides treatment decisions.

The panel highlighted Dr. Malla’s case on liver transplantation for selected metastatic CRC, emphasizing favorable tumor biology, RAS wild-type status, maintenance therapy, and ctDNA- plus imaging-guided surveillance.